Mechanisms of Hypergammaglobulinemia in Pulmonary Sarcoidosis. Site of Increased Antibody Production and Role of T Lymphocytes
Overview
Authors
Affiliations
Pulmonary sarcoidosis is a disorder in which local granuloma formation is perpetuated by activated lung T lymphocytes. The present study suggests that lung T lymphocytes may also play a critical role in modulating local production of antibodies in this disorder. In untreated patients with pulmonary sarcoidosis, the numbers of IgG- and IgM-secreting cells per 10(3) lung lymphocytes are markedly increased compared with those in normal individuals (P < 0.001 and P < 0.01, respectively); the numbers of IgA-secreting cells in lavage fluid of these patients are not increased (P > 0.2). In contrast to lungs, the numbers of IgG-, IgM-, and IgA-secreting cells in blood of patients with this disorder are similar to those in normal individuals (P > 0.2, each comparison). In patients with pulmonary sarcoidosis, there is a direct correlation between the percentage of bronchoalveolar cells that are T lymphocytes and the percentage of bronchoalveolar cells that secrete IgG (r = 0.79; P < 0.001); in normal individuals there is no such relationship (P > 0.2). When purified sarcoid lung T cells from patients with high proportions of T lymphocytes in their lavage fluid were co-cultured with blood mononuclear cells from normal individuals (without added antigens or mitogens), the B lymphocytes in these normal mononuclear cell suspensions were induced to differentiate into immunoglobulin-secreting cells (P < 0.01). In contrast, blood T lymphocytes from these same patients and lung T lymphocytes from sarcoidosis patients with low proportions of T lymphocytes in their lavage fluid did not stimulate normal B cells to produce immunoglobulin (P > 0.2, all comparisons). These findings suggest that in pulmonary sarcoidosis (a) the lung is an important site of immunoglobulin production; (b) activated lung T lymphocytes play an important role in modulating this local production of antibody, and thus are likely to modulate the polyclonal hyperglobulinemia observed in these individuals.
A case report navigating CVID and sarcoidosis overlaps in pediatric nephritis.
Salih A, Brown A, Grimes A, Hasan S, Silva-Carmona M, Tal L Front Pediatr. 2024; 12:1417724.
PMID: 39359743 PMC: 11445013. DOI: 10.3389/fped.2024.1417724.
Buso H, Discardi C, Bez P, Muscianisi F, Ceccato J, Milito C Biomedicines. 2024; 12(7).
PMID: 39062076 PMC: 11275071. DOI: 10.3390/biomedicines12071503.
Clinical Pharmacology in Sarcoidosis: How to Use and Monitor Sarcoidosis Medications.
Kwon S, Judson M J Clin Med. 2024; 13(5).
PMID: 38592130 PMC: 10932410. DOI: 10.3390/jcm13051250.
Advance in pathogenesis of sarcoidosis: Triggers and progression.
Chen C, Luo N, Dai F, Zhou W, Wu X, Zhang J Heliyon. 2024; 10(5):e27612.
PMID: 38486783 PMC: 10938127. DOI: 10.1016/j.heliyon.2024.e27612.
Discovery of Two Novel Immunoepitopes and Development of a Peptide-based Sarcoidosis Immunoassay.
Peng C, Talreja J, Steinbauer B, Shinki K, Koth L, Samavati L Am J Respir Crit Care Med. 2024; 210(7):908-918.
PMID: 38385694 PMC: 11506913. DOI: 10.1164/rccm.202306-1054OC.